Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

InspireMD (NSPR) Research & Development (2016 - 2025)

InspireMD (NSPR) has 16 years of Research & Development data on record, last reported at $3.6 million in Q3 2025.

  • For Q3 2025, Research & Development fell 7.15% year-over-year to $3.6 million; the TTM value through Sep 2025 reached $15.2 million, up 27.1%, while the annual FY2024 figure was $13.6 million, 70.83% up from the prior year.
  • Research & Development reached $3.6 million in Q3 2025 per NSPR's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.1 million in Q1 2025 and bottomed at $839000.0 in Q1 2021.
  • Average Research & Development over 5 years is $2.4 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 190.54% in 2021, then fell 7.15% in 2025.
  • A 5-year view of Research & Development shows it stood at $1.5 million in 2021, then skyrocketed by 31.23% to $2.0 million in 2022, then rose by 1.09% to $2.0 million in 2023, then soared by 81.47% to $3.7 million in 2024, then dropped by 1.57% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $3.6 million in Q3 2025, $3.8 million in Q2 2025, and $4.1 million in Q1 2025.